Skip to main content

Talk Bio

Search This Blog

Biogen trims Apellis R&D after $5.6B acquisition, focuses on Empaveli and Syfovre

on June 29, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Biogen has announced that it will pause or terminate investment in the "majority of legacy Apellis research programs" after completing its $5.6 billion acquisition of Apellis Pharmaceuticals in May 2026. The move is part of Biogen's integration plans and reflects a decision to narrow its R&D focus to the commercialized assets that drove the deal—Empaveli® and Syfovre®, both based on pegcetacoplan. Biogen continues to evaluate Apellis’ remaining clinical and preclinical programs for strategic fit, and has eliminated a small number of research roles within Apellis as part of the pipeline cuts.

Sources:

Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen boosts rare disease pipeline with $5.6bn Apellis buyout deal

Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance

Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout

Biogen Enters $5.6 Billion Agreement to Acquire Apellis ...

Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth By Investing.com

Jack Shuang Hou's Post - LinkedIn

Why Rare Disease Is the New Biotech M&A Battleground - YouTube

Lilly to Buy Sleep Drug Maker; Nvidia Invests $2 Billion in Marvell |...

Biogen scales back Apellis programs, trims research roles after $5.6 ...

Biogen ends Apellis research programs, cuts 'small number' of roles ...

Biogen Secures 'Running Start' in Kidney Disease With $5.6B ...

Gabriel Morelli's Post - LinkedIn

Apellis Acquired by Biogen: Accelerating Growth and Patient Reach

Biogen ends Apellis research programs, cuts 'small number' of roles ...

acquisition Apellis Biogen Complement Inactivating Agents Empaveli Geographic Atrophy Nephrology Speciality pipeline work research program Syfovre

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC